Last reviewed · How we verify
Paracetamol formulation 4
At a glance
| Generic name | Paracetamol formulation 4 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (PHASE1, PHASE2)
- HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis (PHASE2)
- Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery (PHASE3)
- Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) (PHASE1, PHASE2)
- Assessment of the Pharmacokinetics of a Sustained Release Formulation of a Tramadol/Acetaminophen Combination (PHASE1)
- Comparison of the Efficacy, Tolerability and Safety of actiTENS to Those of Level 2 Analgesic Treatments. (NA)
- N-acetylcysteine in Intra-amniotic Infection/Inflammation (PHASE1, PHASE2)
- Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |